The measure has the potential to stymie the continuous flow of stock offers from Chinese technology businesses and pharmaceutical research teams in New York and Hong Kong. The US capital market has risen to the top of the global rankings as the most popular location for global IPOs, including those by Chinese firms./n
Read More
